Washington University School of Medicine
This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
Inclusion Criteria: * Histologically confirmed DTC, defined as papillary, follicular, or Hurthle Cell thyroid cancer. Papillary has several sub-types such as tall-cell and columnar cell, which are all allowed. * Patient must have incurable RAIR DTC, defined as disease not amenable to cure by surgery AND meeting one or more of the following criteria: * one or more sites of disease that do not take up RAI. * disease progression on RAI (given within the last 12 months). * receipt of cumulative dose of RAI of ≥ 600mCi. * patient declines or is ineligible for surgery and/or RAI. * Measura…
Lenvatinib is an oral drug which will be administered on an outpatient basis at a dose of 24 mg daily or 10 mg daily for an unlimited number of cycles.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.